key: cord-0067247-d68g9cku
authors: Zhang, Mei-Xian; Zheng, Bo-Yuan; Chen, Hai-Xiao; Chien, Ching-Wen
title: Clinical effects of antidiabetic drugs on psoriasis: The perspective of evidence-based medicine
date: 2021-08-15
journal: World J Diabetes
DOI: 10.4239/wjd.v12.i8.1141
sha: 698714fcb47335ae9379572d2bb1b32091b848e1
doc_id: 67247
cord_uid: d68g9cku

Psoriasis and diabetes shared common underlying pathophysiological mechanisms. Emerging data suggested that antidiabetic medications may improve the psoriasis severity in patients with diabetes mellitus. Several hypoglycemic agents including thiazolidinediones, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and biguanides have been reported to make a remarkable reduction in the Psoriasis Area and Severity Index score from baseline. This antipsoriatic effect could be mediated not only by the glucose-lowering action of these agents but also via inhibition of keratinocyte over proliferation, increase expression of differentiation markers, suppression the immune inflammatory pathway, and blocking the calcium channels and mitogen-activated protein kinase signaling pathways. On the other hand, there was no significant increase in adverse reactions associated with the treatment of pioglitazone or metformin. However, previous studies often had the relatively short duration of the trials, and did not have enough power to assess recurrence of psoriasis. Potential bias in the study and missing data could undermine the reliability of the results. Therefore, the appropriately randomized controlled studies with large sample sizes and long-term durations in various psoriasis patients are warranted for further support.

Psoriasis is a relatively common disorder, though the prevalence varies among populations. An estimated 29.5 million adults worldwide suffered from psoriasis in 2017, equivalent to a lifetime prevalence of 0.59% (95% uncertainty interval 0.19% to 1.66%) diagnosed by physicians in the global adult population. The estimated prevalence of psoriasis was highest in high income countries such as Australasia (1.58%) and Western Europe (1.52%), and lowest in East Asia (0.11%). However, the highest number of adult populations with psoriasis lived in the United States, India, and China [1] .

Psoriasis is an immune-mediated chronic inflammatory skin disease. The patients' quality of life was seriously affected by a variety of clinical manifestations including characteristic scaly, and itchy and reddish lesions of skin. Furthermore, psoriasis has also been identified as a systemic disorder that involves more than skin. Diabetes mellitus is one of common extra cutaneous disorders in individuals with psoriasis. Growing evidence supports that psoriasis and diabetes are comorbidities of each other and share common underlying pathophysiological mechanisms [2] . Type 1 diabetes is characterized by autoimmune destruction of the pancreatic beta cells. Type 2 diabetes is characterized by insulin resistance and a relative lack of insulin secretion from the beta cells. An altered adipose tissue microenvironment in obesity is responsible for insulin resistance and low-grade inflammation at either local or systemic level (e.g., skin). That said, diabetes can relate with a wide spectrum of skin conditions, including but not limited to psoriasis, due to hyperglycemia-induced microvascular damage, altered immune functions, infections, genetic predisposition, etc. Inflammation can modulate the process of insulin resistance and beta cell damage, and play a critical role in the pathogenesis of type 1 and type 2 diabetes. Thus, antidiabetic drugs with antiinflammatory properties may also have positive effects on treatment of psoriasis, which is the skin manifestation of an inflammatory response. Emerging data suggested that patients with psoriasis may also benefit significantly from antidiabetic medications due to the common immunological pathway and inflammatory signaling pathway [3] [4] [5] [6] .

As we know, psoriasis has no cure, so the main purpose of treatment is to control the disease rather than cure. There are many topical and systematic therapies for treatment of psoriatic skin manifestations. However, most of these treatments are expensive, unavailable or immune suppressive. Accumulating data support that hypoglycemic agents including thiazolidinediones (TZDs), glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), dipeptidyl peptidase-4 (DPP-4) inhibitors, and August 15, 2021 Volume 12 Issue 8 biguanides, take beneficial effects on the treatment of psoriasis.

The peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist TZDs, like pioglitazone, are insulin sensitizers widely used for treatment of diabetes. In recent years, several double-blinded randomized controlled trial (RCT)s showed that TZDs are anti-inflammatory drugs with ameliorating effects on psoriasis[7-11]. In two metaanalysis of 6 RCTs in patients with psoriasis vulgaris, treatment with pioglitazone made a significant 75% or greater improvement in the Psoriasis Area and Severity Index score from baseline (PASI 75) Second, TZDs may be beneficial to psoriasis by reducing the inflammatory response of psoriasis through PPAR-γ. In psoriatic patients, pioglitazone can reduce inflammatory cell infiltration into the skin and reduce the expression of inflammatory cytokines such as C-reactive protein, tumor necrosis factor (TNF) -α and interleukin (IL) 2, and thus inhibit the local immune inflammatory response [14] . Additionally, TZDs could intensify the histology of psoriatic skin via interfering the calcium channels and mitogen-activated protein kinase signaling pathways, but not related to the PPAR effect.

GLP-1-based therapies such as GLP-1 receptor agonists and inhibitors of DPP-4 are effective hypoglycemic agents. GLP-1 is an incretin hormone that regulates glucose metabolism. DPP-4 is a GLP-1 degrading enzyme and exerts its physiological functions particular in lowering blood glucose via the action of GLP-1. Previous study indicated the mechanisms of GLP-1 receptor agonists that determine their antihyperglycemic and anti-inflammatory effects [15] . DPP-4 inhibitors can hinder the DDP-4 to attenuate the degradation of endogenous GLP-1 and prolong the action of GLP-1. A growing body of data shows that GLP-1-based therapies had anti-inflammatory effects in several organs, tissues, and cells through reducing inflammatory cytokine production and immunocyte infiltration. Previous studies on the pathogenesis of psoriasis have focused on keratinocyte excess proliferation, but recently immune system dysfunction has been identified as a critical event. GLP-1 analogues have been reported to alleviate the clinical and histopathology severity of psoriasis through interacting with innate immune system, particularly with invariant natural killer T cells [16] [17] [18] .

A few case reports showed an interest in using GLP-1 RAs as a potentially option in treatment of psoriasis [18] [19] [20] . In a prospective case-series study, seven psoriatic patients with type 2 diabetes following 16-20 wk of GLP-1 RA therapy, alleviated their PASI, and reduced dermal γδT-cell counts, and decreased IL-17 expression levels [21] . Such positive effects on psoriasis severity scores was also observed in other prospective case studies of patients receiving GLP-1 RAs for shorter periods [22, 23] , but the finding was not confirmed in subjects without diabetes [24] . A RCT of 25 patients with psoriasis and type 2 diabetes showed liraglutide treatment for 12 wk led to a reduction in the PASI score and the relative expression levels of inflammatory cytokines such as IL-23, IL-17, and TNF-α in the damaged skin tissues [17] . However, current studies were small sample size or poorly controlled or short-term follow-up, large-scale multi-center randomized controlled trials with a long duration follow-up are still needed for further verification.

Metformin, a synthetic biguanide, is one of the most popular oral glucose-lowering medications approved for treating type 2 diabetes. Metformin has insulin-sensitizing effect, anti-inflammatory effects and proliferation inhibition in keratinocytes by acting adenosine monophosphate-activated protein kinase. Similar to other antidiabetic drugs, metformin use was also found to decrease the risk of psoriasis in a large casecontrol cohort study [25] . Clinical findings demonstrated that metformin can significantly improve psoriasis severity by modulating the immune response [14] . A 17-year population-based real-world cohort study focused on the safety of metformin in psoriatic patients with type 2diabetes and found that metformin did not lead to increased mortality, severe psoriasis, and hospitalizations related to psoriasis. Further dose-response analysis confirmed that metformin is safe for psoriasis patients with diabetes [26] . However, there was only one RCT available for metformin as a potential option in the treatment of psoriasis patients with metabolic syndrome [11, 27] . And the efficacy and safety of metformin in other psoriasis patients have not been determined. Further research in various psoriasis patients is clearly warranted to confirm the preliminary findings.

In conclusion, the current evidence demonstrates that pioglitazone but not rosiglitazone and metformin is effective in treating plaque psoriasis in diabetic patients. On the other hand, the antidiabetic agents do not appear to increase the incidence of adverse effects. However, the relatively short duration of the trials and no enough power to assess recurrence of psoriasis. Due to some biases such as loss to follow-up were observed in previous cohort studies, more RCTs in psoriasis patients with or without diabetes mellitus with a large sample and long observation time are needed for further support.

Ashcroft DM; Global Psoriasis Atlas. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study

Diabetes and Psoriasis: Different Sides of the Same Prism

Glycemic Control in the Treatment of Psoriasis

Effects of antidiabetic drugs on psoriasis: A meta-analysis

The role of PPARγmediated signalling in skin biology and pathology: new targets and opportunities for clinical dermatology

Mechanism of action and effect of immunemodulating agents in the treatment of psoriasis

Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis

Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology

Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial

Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide

Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis

Improvement of psoriasis during exenatide treatment in a patient with diabetes

Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study

Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study

Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study

Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucosetolerant patients--a randomized placebo-controlled trial

Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study

Safety of Metformin in Psoriasis Patients With Diabetes Mellitus: A 17-Year Population-Based Real-World Cohort Study

Randomized Placebo Control Study of Metformin in Psoriasis Patients with Metabolic Syndrome (Systemic Treatment Cohort)